Camp4 Therapeutics Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CAMP Nasdaq 2836 www.camp4tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Camp4 Therapeutics Corporation

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21st, 2026 2:05 pm
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder - May 14th, 2026 5:00 am
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 5:05 pm
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights - May 7th, 2026 2:05 pm
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - Apr 28th, 2026 6:00 am
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 17th, 2026 2:05 pm
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - Apr 13th, 2026 11:36 am
CAMP4 Appoints Michael MacLean to its Board of Directors - Mar 24th, 2026 5:00 am
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - Mar 18th, 2026 12:08 pm
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - Mar 18th, 2026 11:54 am
Biotech Alert: Searches spiking for these stocks today - Mar 12th, 2026 10:25 am
CAMP4 to Participate in Upcoming Investor Conferences - Mar 6th, 2026 2:05 pm
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights - Mar 5th, 2026 2:05 pm
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - Jan 13th, 2026 10:00 am
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 6:00 am
Novo files for CagriSema approval; Merck and Pfizer’s trial win - Dec 19th, 2025 4:01 am
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - Dec 18th, 2025 5:10 am
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries - Dec 18th, 2025 5:00 am
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year - Dec 10th, 2025 3:36 am
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - Nov 6th, 2025 2:05 pm